1. Introduction
Peroxisome biogenesis disorders (PBDs) are inherited disorders primarily caused by pathological variants in any of 14 different
PEX genes. The
PEX genes code for peroxins, proteins involved in peroxisome assembly and importation of peroxisomal matrix proteins [
1]. PBDs are categorized into two groups: rhizomelic chondrodysplasia punctata [
2] and Zellweger spectrum disorders [
3].
Zellweger spectrum disorder (ZSD) is a group of autosomal recessive disorders with a reported incidence of ~1:50,000 births worldwide [
2,
3,
4]. Incidence rates of ZSD, however, have varied dependent on geographical location. A founder disease-causing variant in a French-Canadian population resulted in a regional incidence rate of 1 in 12.191 births [
5], while in Japan the estimated incidence of ZSD is reported to be around 1 in 500,000 births [
6]. A more recent study using a bioinformatics approach reported an estimated incidence of 1 in 83,841 individuals [
7].
The metabolic abnormalities of ZSD typically include elevated very long-chain fatty acids (VLCFAs) and defective bile acid synthesis, contributing to many of the clinical impacts of ZSD [
8]. ZSD can range in severity from severe forms that result in a lifespan of 1–2 years of age to milder forms where patients can live into adulthood [
4,
9]. Affected individuals on the intermediate range of the spectrum often manifest low muscle tone, facial dysmorphism, impaired growth, sensory and neurological dysfunction, renal and endocrine insufficiency, skeletal abnormalities, and developmental delays [
9,
10,
11,
12,
13,
14,
15,
16,
17,
18,
19,
20,
21]. ZSD can also affect nutritional status, including reduced overall growth [
22] and feeding difficulties [
23]. These characteristics of ZSD suggest that dietary intervention may be useful in managing some of the symptoms that affect some individuals with ZSD. Studies in other peroxisomal disorders have shown the benefit of dietary modification for symptom burden. A recent study reported that 96% of a population of patients with adult Refsum disease, a rare metabolic disease caused by a peroxisomal protein deficiency, followed a low-phytanic acid diet under the guidance of a dietitian [
24]. Long-term dietary therapy with a low-phytanic acid diet has been shown to reduce symptom burden and hospital admissions in patients with adult Refsum disease [
25]. A recent clinical trial observed the effects of antioxidant therapy in patients diagnosed with X-linked adrenoleukodystrophy, another peroxisomal protein deficiency disorder [
26]. Previous clinical trials in X-ALD have also looked at the effects of Lorenzo’s oil, a mixture of oils including the fatty acids erucic and oleic acid, but have reported inconclusive results on its efficacy [
27,
28]. In ZSD patients, recent case studies have suggested that dietary intervention may be useful in the management of symptoms [
29,
30]. Moreover, in vitro studies in primary ZSD fibroblasts have suggested that various nutrients, such as amino acids, lipid compounds, and flavonoids, may restore peroxisomal function by acting as molecular chaperones to recover protein folding and importation defects [
31,
32]. However, intervention studies with dietary supplements in patients with ZSD have shown inconsistent results [
33,
34], and, to date, no studies in ZSD have assessed dietary intake as a measurement outcome in clinical studies for ZSD.
Due to the neurological impairment in moderate to severe ZSD, dietary assessments need to be modified from the traditional assessment methodology. In most cases, caregiver reports of dietary intake (as opposed to patient self-report) may be required due to speech difficulties and cognitive impairment. Additionally, many patients with ZSD require enteral feeding to address feeding difficulties [
23]. To date, there are very few studies that have critically analyzed dietary assessment in children that require enteral feeding, despite studies that show that children on enteral feeding are at higher nutritional risk than orally fed children [
35,
36]. Moreover, many studies often exclude children who are enterally fed in dietary assessment studies conducted in neurologically impaired children [
37]. Overall, there is little evidence-based guidance on conducting dietary assessments in children with cognitive delays and speech impairment, as well as in children who receive enteral feedings.
The primary purpose of this study was to determine the overall nutrient intake in subjects with ZSD or a related single-enzyme peroxisomal disorder, using the input of family caregivers. We conducted a series of dietary assessments (24 h dietary recalls and 3-day food records) at three time points to verify that these dietary assessments could provide reliable assessments of dietary intake in order to determine the overall nutrient intake in subjects with ZSD and related single-enzyme peroxisomal disorders. We partnered with the Global Foundation for Peroxisomal Disorders (GFPD;
http://www.thegfpd.org; accessed on 21 January 2025), a patient advocacy group focused on ZSD and related peroxisomal disorders, to execute this study.
4. Discussion
In the current study, we present the overall energy and nutrient intake of individuals with ZSD or a related single-enzyme peroxisomal disorder as determined by caregiver report. Additionally, we show the consistent reporting of dietary intake by caregivers on their affected children across two different methods of dietary assessment. To our knowledge, this is the first report of dietary intake in individuals with these disorders. Our study shows that, according to both 24 h recall and 3-day food records, patients, on average, were achieving or exceeding their daily requirements (as determined by DRI, established by the IOM) for energy, carbohydrate, protein, and total fat intake. Mean protein intake was greater than 2.5 times the daily requirements, with nearly all patients individually consuming 1.5 times the recommended amounts of protein daily or higher. These data suggest that patients should at least be consuming food and beverages to meet their estimated energy expenditure calorie requirement. Additionally, patients may need at least 1.5 times more protein than their DRI to maintain growth requirements. Although no overt kidney symptoms were reported in our study, kidney function has been recommended to be monitored in patients with ZSD [
42] and should be followed in patients for both ZSD-related symptoms and the impacts of protein intake on the kidneys.
Our findings on adequate or higher than adequate macronutrient intake are in spite of the fact that a third of the patients in this study were underweight and the majority of patients were at or below the 10th percentile for stature. Failure to thrive is a common characteristic in ZSD and related peroxisomal disorders, and either increased caloric/macronutrient intake or enteral tube placement are often prescribed in these patients to address the failure-to-thrive diagnosis [
42]. The findings of our study suggest that either calorie and nutrient requirements are higher in patients with ZSD compared to the age-matched reference values established by the IOM, or that there is altered growth in individuals with ZSD. Given the low muscle tone present in ZSD and related disorders and its general impact of reduced mobility [
23], energy expenditure is likely not higher in these patients. However, bile acid synthesis defects are a common occurrence in moderate to severe ZSD [
43], which may affect nutrient absorption, particularly the absorption of fat and fat-soluble vitamins. Therefore, calorie and nutrient requirements may be higher in patients with ZSD and related disorders due to nutrient malabsorption. Future studies will need to determine whether or not nutrient malabsorption is a significant contributor to growth issues in this patient population.
Regarding the possibility of altered growth in ZSD and related disorders, bone mineral density is often reduced in moderate to severe ZSD [
10], and a 2017 paper published a disease-specific growth chart for rhizomelic chondrodysplasia punctata (RCDP), another peroxisome biogenesis disorder, based on decreased growth potential in these patients [
44]. Growth monitoring in ZSD is recommended periodically in patients, and a 2018 study that developed a tool to measure disease severity in patients with ZSD included growth as one of its measurement domains [
45]. Taken together with our data, there may be a need for a condition-specific growth chart for ZSD and related disorders.
Fiber was the only nutrient whose consumption was consistently lower in our patients compared to the recommended intakes. Inadequate fiber intake is a common public health problem among all children and adults in the United States [
46]. Similarly, sugar consumption was consistently above the recommended intake levels for almost all subjects in this study, which aligns with sugar consumption trends among children in the United States [
47,
48]. Strategies to address these issues in individuals with ZSD or a related peroxisomal disorder should follow general recommendations to increase fiber intake and decrease sugar intake. However, on an individual basis, it is important that families discuss any considerable dietary changes with their medical professionals before implementation to avoid any potential adverse effects.
Mean intake of micronutrients, as determined by recall or food record, was also adequate or above DRI requirements among our subjects. Mean fat-soluble vitamin intake ranged from approximately 2.5 times over the DRI (for vitamin D) to over 200 times the DRI (for vitamin K). Malabsorption of fat-soluble vitamins due to bile acid synthesis defects has been characterized in ZSD, and fat-soluble vitamin supplementation is recommended to severe and moderate ZSD patients [
42]. Mean vitamin K intake was particularly high compared to the other fat-soluble vitamins; this was likely meant to reduce the risk of coagulopathy often observed in moderate to severe ZSD due to liver dysfunction and vitamin K malabsorption [
13]. The majority of the patients studied were taking additional vitamin K supplements above and beyond the standard fat-soluble supplementation that is recommended for patients with moderate to severe ZSD [
42].
For all nutrients studied, we observed statistically significant correlations between caregiver reports of dietary intake by 24 h dietary recall vs. 3-day food recall in patients. This shows that the caregiver reporting of dietary intake was consistent across the methodologies in this study, suggesting that caregivers of these patients can provide an accurate assessment of food intake, and, consequently, these data can be used as measurable outcomes in clinical practice and research. Our data serve as a proof of concept to conduct possible dietary intervention studies with nutrients that may reduce symptom burden in ZSD. As an example, docosahexaenoic acid (DHA) is an essential polyunsaturated fatty acid (C22:6) important for neuronal cell communication as well as retinal function [
49]. Peroxisomes are the primary sites of DHA metabolism [
50], and individuals with ZSD have been shown to have reduced levels of DHA in brain tissue [
51]. Intervention studies with DHA supplementation to date, however, have yielded inconsistent results regarding its effectiveness in patients with ZSD [
33,
34,
52]. It should be noted that none of these studies included a full dietary assessment of subjects with respect to food, beverage, and supplement intake. Depending on the DHA supplement dose used in these studies, the overall dietary contribution of DHA may have been a confounding variable in these studies. Taken together, there may be a rationale for more controlled clinical trials with DHA supplementation that include a comprehensive dietary assessment of DHA intake as well as other nutrients.
Additionally, there is a growing interest in the role of phytonutrients such as flavonoids from the diet and in supplement form in the management of neurodegenerative diseases in adults [
53]. An in vitro study of fibroblasts derived from ZSD patients showed that diosmetin and other related flavanols restored peroxisomal activity [
54]. These data suggest that dietary supplementation of flavanols may be useful in the management of symptoms of ZSD by restoring peroxisomal activity; a dietary intervention study with dietary assessment outcomes would be warranted in this case.
The correlation between methodologies was stronger for macronutrient intake compared to micronutrient intake. Additionally, the effect size was significant across 24 h recall and 3-day food records for three micronutrients, including vitamin E, iron, and sodium. This may be due to the fact that the majority of caregivers considered dietary supplements as their child’s primary source of micronutrient intake as supplements and may have been less consistent with supplement intake compared to actual food and beverage intake. Indeed, in our supplement assessment, some caregivers reported their child missing days of taking their dietary supplements, which may have resulted in differences in intake across the two assessment methods.
Between the two dietary assessment methodologies, the 3-day food record approach has been associated with greater respondent burden compared to the 24 h recall method [
55]. Considering the heavy burden of responsibilities that caregivers of patients with ZSD experience [
56], the 24 h dietary recall may be the more appropriate methodology to conduct dietary assessments in families affected by ZSD or disorders with a similar burden.
Although this study presents new findings on dietary intake of individuals diagnosed with ZSD or a related single-enzyme peroxisomal disorder, there are some limitations to the research. First, given the rarity of these disorders, our sample size was small, and our subjects were spread out across the United States, Canada, and the United Kingdom. Therefore, we were unable to conduct in-person assessments. As a result, we relied on caregiver reporting of height and weight based on their child’s last physician appointment. This may have played a role in some inaccuracies in height and weight. Additionally, although both recall and food records were highly correlated across nutrient intake, suggesting that caregivers can report on their child’s food intake consistently across the two methodologies, we cannot definitively say that these reports were an accurate reflection of actual intake, as both sets were caregiver reports and were not compared against a more absolute measure, such as biomarkers of nutrient levels in blood samples. Future studies will need to compare dietary intake with laboratory data to confirm the accuracy of nutrient intake methods.
It is possible that the strong correlations in nutrient intake between the different dietary assessment methods are due to the fact that many enterally fed patients likely receive the same formula and volume every day, which would lend to its consistency across dietary assessment methods. Conversely, some of the differences observed in micronutrient intake across assessment methods may also be partially attributable to feeding modality. Future studies will tease out nutrient intake and correlations between assessment methods in orally and enterally fed patients to see if there are differences in outcomes across these different feeding modalities.
Our study used the IOM DRIs as the reference values for energy and nutrient intake due to their accounting for age in recommended intakes. Some research has suggested that IOM estimated energy requirements overestimate caloric needs, although this overestimation has been generally observed in obese subjects [
57]. As our subjects are not obese and are potentially at risk for undernutrition, our observation of adequate or higher than adequate intake among our subjects against IOM DRIs further supports that our subjects are meeting their caloric and nutrient needs.